Microalbuminuria - A biomarker of renal microvascular disease

Renal Failure

Volumn 31, Issue 2, 2009, Pages 140-143

  Futrakul, Narisa ^a   Sridama, Vitaya ^a   Futrakul, Prasit ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

FE Mg; Hemodynamics; Microalbuminuria; Podocyte; Renal microvascular disease

Indexed keywords

ALBUMIN; CYTOKINE;

CAPILLARY PERMEABILITY; CELL DAMAGE; DISEASE MARKER; ELECTRICITY; ENDOTHELIAL DYSFUNCTION; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; MICROALBUMINURIA; MICROANGIOPATHY; MICROVASCULATURE; MOLECULAR MECHANICS; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; REVIEW;

ALBUMINURIA; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MICROVESSELS; PODOCYTES;

EID: 61649096404     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802595948     Document Type: Review

References (42)

1. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006;17:2100-2105.
2. Parving HH, Lewis JB, Ravid M, Remuzzi M, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int. 2006;69:2057-2063.
3. Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM, Welborn TA, Atkins RC. Albuminuria is evident in the early stages of diabetes onset: Results from the Australian Diabetes, Obesity, and Lifestyle Study (Aus-Diab). Am J Kidney Dis. 2004;44:792-798.
4. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225-232.
5. Ruggenenti P, Fussi A, Illieva AP, Bruno S, Illier IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Enelordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complicaions Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;331:1941-1951.
6. Parving HH, Mogensen CE, Jensen HA, Ervin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet. 1974;1:1190-1192.
7. Atkins RC. The epidemiology of chronic kidney disease. Kidney Int Suppl. 2005;67:S14-S18.
8. Hillege HL, Janssen WM, Bak AA, Diercks GF, Gubbee DE, Crijns HJ, Van Gilst WH, De Zeeu WD, De Jong PE; PREVEND Study Group. Microalbuminuria is common, also in a nondiabetic, non hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001;249:519-526.
9. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlof B, Gerdts E, Wright JT Jr, Papadermetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Losartan Intervention for Endpoint Reduction. Am Hent J. 2002;43: 319-326.
10. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
11. Stchouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. J Am Soc Nephrol. 2006;17:2106-2111.
12. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion - a predictor of risk of cardiovascular disease: A prospective 10-year follow-up of middle aged nondiabetic normal and hypertensive men. Am J Hypertens. 1996;9:770-778.
13. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Jchroll M, Jensen JS. Urinary albumin excretion: An independent predictor of ischemic heart disease. Arteioscler Thromb Vasc Biol. 1999;19:1992-1997.
14. Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FIR. Effect of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: A three-year placebo controlled biopsy study. Metabolism 1998;47(Suppl. 1):12-15.
15. Oagtakybab ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342-348.
16. Foretto P, Maner M, Bortoloso E, et al. Glomerular ultrastructure in type 2 diabetes (abstract). J Am Soc Nephrol 1998;9:114A.
17. Moriya T, Moriya R, Yajima Y, et al. Urinary albumin as an indicator of diabetic nephropathy lesions in Japanese type 2 diabetic patients. Nephron 2002;91:292-299.
18. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol 2006;17:2120-2126.
19. Futrakul N, Vongthavarawat V, Sirisalipotch S, et al. Tubular dysfunction and hemodynamic alteration in normoalbuminuric type 2 diabetes. Clin Hemorheol Microcirc. 2005;32:59-65.
20. Futrakul N, Sila-asna M, Futrakul P. Therapeutic strategy towards renal restoration in chronic kidney disease. Asian Biomedicine. 2007;1:33-44.
21. Futrakul P, Yenrudi S, Futrakul N, Sensirivatana R, Kingwatanakul P, Jungthirapanich J, et al. Tubular function and tubulointerstitial disease. Am J Kidney Dis. 1999;33:886-891.
22. Futrakul N, Butthep P. Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy. Ren Fail. 2005;27:493-494.
23. Futrakul P, Tosukhowong P, Valyapongpichit Y, Tipprukmas N, Futrakul P, Patumraj S. Oxidative stress and hemodynamic maladjustment in chronic renal disease: A therapeutic implication. Ren Fail. 2002;24:433-445.
24. Futrakul N, Tosukhowong P, Patumraj S, Siriviriyakul P, Tipprukmas N, Futrakul P. Treatments of hemodynamic maladjustment and oxidative stress prevent renal disease progression in chronically serve glomerulonephritdes. Ren Fail. 2003;25:839-844.
25. Deekajorndech T. Fractional excretion of magnesium (FE Mg) in systemic lupus erythematosus. J Med Assoc Thai. 2005;88:743-745.
26. Deekajorndech T. Biomarker for detecting early tubulointerstitial disease and ischemia in glomerulopathies. Ren Fail. 2007;29:1013-1017.
27. Futrakul N, Panichakul T, Butthep P, Futrakul P, Jetanalin P, Patumraj S, et al. Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis (FSGS) nephrosis. Clin Hemorheol Microcirc. 2004;31:267-272.
28. Futrakul N, Butthep P, Patumraj S, Siriviriyakul P, Futrakul P. Microvascular disease and endothelial dysfunction in chronic kidney disease: Therapeutic implication. Clin Hemorheol Microcirc. 2006;34:265-271.
29. Futrakul P, Poshyachinda M, Yenrudi S, Salikul P, Sensirivatana R, Futrakul N, et al. Intrarenal hemodynamic abnormality in severe form of glomerulonephritis: Therapeutic benefit with vasodilators. J Med Assoc Thai. 1992;75: 375-385.
30. Futrakul N, Laohaphaibul A, Futrakul P. Glomerular endothelial dysfunction and hemodynamic maladjustment in severe vesicoureteric reflux. Ren Fail. 2003;25:479-483.
31. Futrakul N, Futrakul P, Siriviriyakul P. Correction of peritubular capillary flow reduction with vasodilators restores function in focal segmental glomerulosclerotic nephrosis. Clin Hemorheol Microcirc. 2004;31:197-205.
32. Liang XB, Ma LJ, Naito T, Wang Y, Madaio M, Zent R, Pozzi A, Fogo AB. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol. 2006;17:1886-1895.
33. Satchell SC, Herper SJ, Tooke JE, Kerjaschki D, Saleem MA, Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol. 2002;13:544-550.
34. Kriz W, Elger M, Nagata M, Kactzler M, Uiker S, Koeppen-Hageman I, et al. The role of podocytes in the development of glomerulosclerosis. Kidney Int. 1994;45 (Suppl.):S64-S72.
35. Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int. 1994;45 (Suppl.):S58-S63.
36. Shulman K, Resen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol. 1996;7:661-666.
37. Futrakul N, Butthep P, Chunhakarn S, Banyatsappasin W. A deficient EGF enhances endothelial cell loss and impaired renal function. Ren Fail. 2006;28:449.
38. Futrakul N, Yenrudi S, Sensirivatana R, Watana D, Laohaphaibul A, Watanapenphaibul K, et al. Peritubular capillary flow determines tubulointerstitial disease in idiopathic nephrotic syndrome. Ren Fail. 2000;22:329-335.
39. Futrakul N, Butthep P, Futrakul P. Altered vascular homeostasis in chronic kidney disease. Clin Hemorheol Microcirc. 2008;38:201-207.
40. Futrakul N, Futrakul P. Renal microvascular disease in aging population: A reversible process? Ren Fail. 2008;30:353-356.
41. Verzola D, Gandolfo MT, Ferrario F, Rastoldi MP, Villaggio B, Gieniorio F, et al. Response to renal microvascular and tubular injuries in type II diabetic nephropathy. Kidney Int. 2008;74:390-391.
42. Futrakul N, Futrakul P. Renal microvascular and tubular injuries in type II diabetic nephropathy. Kidney Int. 2008;74:390.